We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Veeva's Vault Vision: Can It Thrive After Parting With Salesforce?
Read MoreHide Full Article
Key Takeaways
VEEV saw strong client feedback on Vault, with smoother integration and improved performance reported.
VEEV targets full Salesforce independence by September 2025 to boost control and innovation via Vault.
VEEV is investing heavily in R&D and support to ease the transition and drive long-term differentiation.
Veeva Systems (VEEV - Free Report) is entering a pivotal phase as it gradually transitions away from Salesforce’s infrastructure, aiming to complete the shift by the end of September 2025. This move marks a significant step toward full platform independence, allowing Veeva to operate entirely on its proprietary Vault architecture. The strategy is designed to give Veeva greater control over product development, performance, and long-term innovation — especially as the company deepens its focus on delivering purpose-built software for the life sciences sector. Early signs are promising, with many clients already reporting smoother integration and more consistent performance on Vault.
Veeva’s recent performance shows just how central the Vault platform has become to its long-term growth story. Veeva has also been proactive in helping its Commercial Cloud customers prepare for the shift, offering migration roadmaps and hands-on support to ease the transition. While increased investment in R&D and customer onboarding may weigh on margins in the short term, Veeva appears focused on the bigger picture, owning its infrastructure to drive faster innovation and long-term differentiation in a highly specialized market.
Peers Update
For Salesforce (CRM - Free Report) , the conclusion of its infrastructure partnership with Veeva marks a natural evolution as both companies refine their long-term strategies. While Veeva was a high-profile example of Salesforce’s presence in life sciences, its shift reflects a broader industry trend toward purpose-built platforms. Salesforce continues to expand its healthcare and life sciences offerings through initiatives like Health Cloud and Data Cloud, aiming to meet the growing demand for tailored solutions. Although adoption varies across segments, Salesforce remains a key player with a broad enterprise footprint and a strong innovation pipeline.
IQVIA (IQV - Free Report) , a major player in the life sciences technology space, continues to compete through its deep data assets and broad service offerings. While its technology stack is not as tightly integrated as Veeva’s, IQVIA’s scale and diversified model give it a different kind of competitive edge. As Veeva builds out its post-Salesforce identity, IQVIA remains a key peer to watch — particularly in areas where data services and real-world evidence intersect with software.
Veeva Systems’ Price Performance, Valuation and Estimates
Shares of VEEV have gained 36% in the year-to-date period compared with the industry’s growth of 8.2%.
Image Source: Zacks Investment Research
From a valuation standpoint, Veeva trades at a forward price-to-sales ratio of 14.3, above the industry average. VEEV carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for VEEV’s fiscal 2026 earnings implies a 15.8% rise from the year-ago period.
Image: Bigstock
Veeva's Vault Vision: Can It Thrive After Parting With Salesforce?
Key Takeaways
Veeva Systems (VEEV - Free Report) is entering a pivotal phase as it gradually transitions away from Salesforce’s infrastructure, aiming to complete the shift by the end of September 2025. This move marks a significant step toward full platform independence, allowing Veeva to operate entirely on its proprietary Vault architecture. The strategy is designed to give Veeva greater control over product development, performance, and long-term innovation — especially as the company deepens its focus on delivering purpose-built software for the life sciences sector. Early signs are promising, with many clients already reporting smoother integration and more consistent performance on Vault.
Veeva’s recent performance shows just how central the Vault platform has become to its long-term growth story. Veeva has also been proactive in helping its Commercial Cloud customers prepare for the shift, offering migration roadmaps and hands-on support to ease the transition. While increased investment in R&D and customer onboarding may weigh on margins in the short term, Veeva appears focused on the bigger picture, owning its infrastructure to drive faster innovation and long-term differentiation in a highly specialized market.
Peers Update
For Salesforce (CRM - Free Report) , the conclusion of its infrastructure partnership with Veeva marks a natural evolution as both companies refine their long-term strategies. While Veeva was a high-profile example of Salesforce’s presence in life sciences, its shift reflects a broader industry trend toward purpose-built platforms. Salesforce continues to expand its healthcare and life sciences offerings through initiatives like Health Cloud and Data Cloud, aiming to meet the growing demand for tailored solutions. Although adoption varies across segments, Salesforce remains a key player with a broad enterprise footprint and a strong innovation pipeline.
IQVIA (IQV - Free Report) , a major player in the life sciences technology space, continues to compete through its deep data assets and broad service offerings. While its technology stack is not as tightly integrated as Veeva’s, IQVIA’s scale and diversified model give it a different kind of competitive edge. As Veeva builds out its post-Salesforce identity, IQVIA remains a key peer to watch — particularly in areas where data services and real-world evidence intersect with software.
Veeva Systems’ Price Performance, Valuation and Estimates
Shares of VEEV have gained 36% in the year-to-date period compared with the industry’s growth of 8.2%.
Image Source: Zacks Investment Research
From a valuation standpoint, Veeva trades at a forward price-to-sales ratio of 14.3, above the industry average. VEEV carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for VEEV’s fiscal 2026 earnings implies a 15.8% rise from the year-ago period.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.